Opexa Therapeutics (OPXA -2.9%) trades lower after the company reported a deeper Q2 loss and issued an update on its quarterly corporate developments. Losses grew as R&D costs nearly doubled on the company's preparation for Phase II trials of its lead MS drug therapy Tcelna. Additionally, the company says it's closed financing of its $4.1M private offering, and appointed current board member David Jorden as CFO, effective August 15.